Resolution Therapeutics Secures $63.5 Million in Series B Funding to Revolutionize Treatment for Chronic Liver Disease

Resolution Therapeutics, a pioneering biotechnology company based at the Centre for Regenerative Medicine on the Edinburgh Royal Infirmary Campus, has successfully raised an impressive $63.5 million in its latest funding round. This significant capital infusion comes on the heels of a fruitful collaboration between the Centre, the Scottish National Blood Transfusion Service, and Syncona Investment Management Limited. Specializing in groundbreaking macrophage cell therapy, Resolution Therapeutics is poised to tackle chronic liver disease, an unsettling condition that continues to escalate in western countries, affecting millions and severely impacting their quality of life. Current treatment options are limited to supportive care, leaving patients with end-stage liver disease with no choice but to consider liver transplantation—a complex and often unattainable surgical option due to donor shortages and medical complications. With the newly acquired funds, Resolution Therapeutics aims to advance its macrophage cell therapy product through clinical development, targeting patients at risk of liver decompensation. This innovative approach not only represents a potential lifeline for those struggling with chronic liver disease but also seeks to relieve the tremendous burden on healthcare systems by reducing the reliance on organ transplants. As the company forges ahead, it remains dedicated to transforming the landscape of liver disease treatment and ultimately improving patient outcomes through its pioneering cell therapy solutions.